PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial
Context: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. Objective: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surg...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2016-11, Vol.101 (11), p.4039-4045 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4045 |
|---|---|
| container_issue | 11 |
| container_start_page | 4039 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 101 |
| creator | Palermo, Andrea Mangiameli, Giuseppe Tabacco, Gaia Longo, Filippo Pedone, Claudio Briganti, Silvia Irina Maggi, Daria Vescini, Fabio Naciu, Anda Lauria Pantano, Angelo Napoli, Nicola Angeletti, Silvia Pozzilli, Paolo Crucitti, Pierfilippo Manfrini, Silvia |
| description | Context:
There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia.
Objective:
Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery.
Design:
This was a prospective phase II randomized open-label trial.
Setting:
This trial was set on a surgical ward.
Patients:
Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
Intervention:
Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
Main Outcome Measure:
Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured.
Results:
Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09–0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04)
Conclusions:
Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and vitamin D supplementation after discharge in high risk subjects after thyroid surgery.
Teriparatide may prevent post-thyroidectomy hypocalcemia, shorten the duration of hospitalization and reduce the need for calcium and vitamin D supplementation after discharge. |
| doi_str_mv | 10.1210/jc.2016-2530 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835427859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/jc.2016-2530</oup_id><sourcerecordid>1835427859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4789-6ff09d81f3ef0901a8092bfb280ea2408c44621d59e3b875adfc245411ea6ed63</originalsourceid><addsrcrecordid>eNp1kM-K1EAQxhtxccfVm2cJeHCFzdrVf5KON1nUERZ2wAjqpenpVJiMSTp2Jy5z8x18Q5_EDhkVRAuKqoZffXz9EfII6CUwoM_39pJRyFImOb1DVlAImeZQ5HfJilIGaZGzD6fkfgh7SkEIye-RU5ZLJiVnK_JpU67P4ce371w8S2rnk3GHycY3nfGHOPEr9mPj-sTVycaFcdwdvGsqtKPrDsn6MDhrWotdY14kZbws1x83N--S0jemfUBOatMGfHicZ-T961fl1Tq9vnnz9urldWpFroo0q2taVApqjnGhYBQt2LbeMkXRMEGVFSJjUMkC-Vbl0lS1ZUIKADQZVhk_I-eL7uDdlwnDqLsmWGxb06ObggbFpWC5kkVEn_yF7t3k--hOc8gEz3kmVKQuFsp6F4LHWg9LIBqonjPXe6vnzPWcecQfH0WnbYfVb_hXyBEQC3Dr2hF9-NxOt-j1Dk077jSNJbJcpbMiQHylsWE2-3Q5c9PwPwfp0QFfSOwrZ33T4-AxhD-f-6fvn9_4pzI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3164373648</pqid></control><display><type>article</type><title>PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial</title><source>MEDLINE</source><source>Oxford Journals - Connect here FIRST to enable access</source><source>Free E-Journal (出版社公開部分のみ）</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Palermo, Andrea ; Mangiameli, Giuseppe ; Tabacco, Gaia ; Longo, Filippo ; Pedone, Claudio ; Briganti, Silvia Irina ; Maggi, Daria ; Vescini, Fabio ; Naciu, Anda ; Lauria Pantano, Angelo ; Napoli, Nicola ; Angeletti, Silvia ; Pozzilli, Paolo ; Crucitti, Pierfilippo ; Manfrini, Silvia</creator><creatorcontrib>Palermo, Andrea ; Mangiameli, Giuseppe ; Tabacco, Gaia ; Longo, Filippo ; Pedone, Claudio ; Briganti, Silvia Irina ; Maggi, Daria ; Vescini, Fabio ; Naciu, Anda ; Lauria Pantano, Angelo ; Napoli, Nicola ; Angeletti, Silvia ; Pozzilli, Paolo ; Crucitti, Pierfilippo ; Manfrini, Silvia</creatorcontrib><description>Context:
There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia.
Objective:
Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery.
Design:
This was a prospective phase II randomized open-label trial.
Setting:
This trial was set on a surgical ward.
Patients:
Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
Intervention:
Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
Main Outcome Measure:
Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured.
Results:
Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09–0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04)
Conclusions:
Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and vitamin D supplementation after discharge in high risk subjects after thyroid surgery.
Teriparatide may prevent post-thyroidectomy hypocalcemia, shorten the duration of hospitalization and reduce the need for calcium and vitamin D supplementation after discharge.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2016-2530</identifier><identifier>PMID: 27525532</identifier><language>eng</language><publisher>United States: Endocrine Society</publisher><subject>Calcitriol ; Calcitriol - therapeutic use ; Calcium (blood) ; Calcium carbonate ; Calcium, Dietary - therapeutic use ; Dietary Supplements ; Drug Administration Schedule ; Female ; Goiter, Nodular - surgery ; Graves Disease - surgery ; Hormone Replacement Therapy - adverse effects ; Hospitalization ; Hospitals, University ; Humans ; Hypocalcemia ; Hypocalcemia - blood ; Hypocalcemia - epidemiology ; Hypocalcemia - etiology ; Hypocalcemia - prevention & control ; Incidence ; Injections, Subcutaneous ; Italy - epidemiology ; Length of Stay ; Male ; Middle Aged ; Parathyroid hormone ; Parathyroid Hormone - blood ; Patients ; Postoperative Complications - blood ; Postoperative Complications - epidemiology ; Postoperative Complications - etiology ; Postoperative Complications - prevention & control ; Prevention ; Risk ; Surgery ; Teriparatide - administration & dosage ; Teriparatide - adverse effects ; Teriparatide - therapeutic use ; Thyroid ; Thyroid gland ; Thyroid Neoplasms - surgery ; Thyroidectomy ; Thyroidectomy - adverse effects ; Vitamin D</subject><ispartof>The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4039-4045</ispartof><rights>Copyright © 2016 by the Endocrine Society</rights><rights>Copyright © 2016 by the Endocrine Society 2016</rights><rights>Copyright © 2016 by The Endocrine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4789-6ff09d81f3ef0901a8092bfb280ea2408c44621d59e3b875adfc245411ea6ed63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27525532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palermo, Andrea</creatorcontrib><creatorcontrib>Mangiameli, Giuseppe</creatorcontrib><creatorcontrib>Tabacco, Gaia</creatorcontrib><creatorcontrib>Longo, Filippo</creatorcontrib><creatorcontrib>Pedone, Claudio</creatorcontrib><creatorcontrib>Briganti, Silvia Irina</creatorcontrib><creatorcontrib>Maggi, Daria</creatorcontrib><creatorcontrib>Vescini, Fabio</creatorcontrib><creatorcontrib>Naciu, Anda</creatorcontrib><creatorcontrib>Lauria Pantano, Angelo</creatorcontrib><creatorcontrib>Napoli, Nicola</creatorcontrib><creatorcontrib>Angeletti, Silvia</creatorcontrib><creatorcontrib>Pozzilli, Paolo</creatorcontrib><creatorcontrib>Crucitti, Pierfilippo</creatorcontrib><creatorcontrib>Manfrini, Silvia</creatorcontrib><title>PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context:
There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia.
Objective:
Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery.
Design:
This was a prospective phase II randomized open-label trial.
Setting:
This trial was set on a surgical ward.
Patients:
Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
Intervention:
Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
Main Outcome Measure:
Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured.
Results:
Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09–0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04)
Conclusions:
Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and vitamin D supplementation after discharge in high risk subjects after thyroid surgery.
Teriparatide may prevent post-thyroidectomy hypocalcemia, shorten the duration of hospitalization and reduce the need for calcium and vitamin D supplementation after discharge.</description><subject>Calcitriol</subject><subject>Calcitriol - therapeutic use</subject><subject>Calcium (blood)</subject><subject>Calcium carbonate</subject><subject>Calcium, Dietary - therapeutic use</subject><subject>Dietary Supplements</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Goiter, Nodular - surgery</subject><subject>Graves Disease - surgery</subject><subject>Hormone Replacement Therapy - adverse effects</subject><subject>Hospitalization</subject><subject>Hospitals, University</subject><subject>Humans</subject><subject>Hypocalcemia</subject><subject>Hypocalcemia - blood</subject><subject>Hypocalcemia - epidemiology</subject><subject>Hypocalcemia - etiology</subject><subject>Hypocalcemia - prevention & control</subject><subject>Incidence</subject><subject>Injections, Subcutaneous</subject><subject>Italy - epidemiology</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>Patients</subject><subject>Postoperative Complications - blood</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - etiology</subject><subject>Postoperative Complications - prevention & control</subject><subject>Prevention</subject><subject>Risk</subject><subject>Surgery</subject><subject>Teriparatide - administration & dosage</subject><subject>Teriparatide - adverse effects</subject><subject>Teriparatide - therapeutic use</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><subject>Thyroid Neoplasms - surgery</subject><subject>Thyroidectomy</subject><subject>Thyroidectomy - adverse effects</subject><subject>Vitamin D</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM-K1EAQxhtxccfVm2cJeHCFzdrVf5KON1nUERZ2wAjqpenpVJiMSTp2Jy5z8x18Q5_EDhkVRAuKqoZffXz9EfII6CUwoM_39pJRyFImOb1DVlAImeZQ5HfJilIGaZGzD6fkfgh7SkEIye-RU5ZLJiVnK_JpU67P4ce371w8S2rnk3GHycY3nfGHOPEr9mPj-sTVycaFcdwdvGsqtKPrDsn6MDhrWotdY14kZbws1x83N--S0jemfUBOatMGfHicZ-T961fl1Tq9vnnz9urldWpFroo0q2taVApqjnGhYBQt2LbeMkXRMEGVFSJjUMkC-Vbl0lS1ZUIKADQZVhk_I-eL7uDdlwnDqLsmWGxb06ObggbFpWC5kkVEn_yF7t3k--hOc8gEz3kmVKQuFsp6F4LHWg9LIBqonjPXe6vnzPWcecQfH0WnbYfVb_hXyBEQC3Dr2hF9-NxOt-j1Dk077jSNJbJcpbMiQHylsWE2-3Q5c9PwPwfp0QFfSOwrZ33T4-AxhD-f-6fvn9_4pzI</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Palermo, Andrea</creator><creator>Mangiameli, Giuseppe</creator><creator>Tabacco, Gaia</creator><creator>Longo, Filippo</creator><creator>Pedone, Claudio</creator><creator>Briganti, Silvia Irina</creator><creator>Maggi, Daria</creator><creator>Vescini, Fabio</creator><creator>Naciu, Anda</creator><creator>Lauria Pantano, Angelo</creator><creator>Napoli, Nicola</creator><creator>Angeletti, Silvia</creator><creator>Pozzilli, Paolo</creator><creator>Crucitti, Pierfilippo</creator><creator>Manfrini, Silvia</creator><general>Endocrine Society</general><general>Oxford University Press</general><general>Copyright by The Endocrine Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201611</creationdate><title>PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial</title><author>Palermo, Andrea ; Mangiameli, Giuseppe ; Tabacco, Gaia ; Longo, Filippo ; Pedone, Claudio ; Briganti, Silvia Irina ; Maggi, Daria ; Vescini, Fabio ; Naciu, Anda ; Lauria Pantano, Angelo ; Napoli, Nicola ; Angeletti, Silvia ; Pozzilli, Paolo ; Crucitti, Pierfilippo ; Manfrini, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4789-6ff09d81f3ef0901a8092bfb280ea2408c44621d59e3b875adfc245411ea6ed63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Calcitriol</topic><topic>Calcitriol - therapeutic use</topic><topic>Calcium (blood)</topic><topic>Calcium carbonate</topic><topic>Calcium, Dietary - therapeutic use</topic><topic>Dietary Supplements</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Goiter, Nodular - surgery</topic><topic>Graves Disease - surgery</topic><topic>Hormone Replacement Therapy - adverse effects</topic><topic>Hospitalization</topic><topic>Hospitals, University</topic><topic>Humans</topic><topic>Hypocalcemia</topic><topic>Hypocalcemia - blood</topic><topic>Hypocalcemia - epidemiology</topic><topic>Hypocalcemia - etiology</topic><topic>Hypocalcemia - prevention & control</topic><topic>Incidence</topic><topic>Injections, Subcutaneous</topic><topic>Italy - epidemiology</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>Patients</topic><topic>Postoperative Complications - blood</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - etiology</topic><topic>Postoperative Complications - prevention & control</topic><topic>Prevention</topic><topic>Risk</topic><topic>Surgery</topic><topic>Teriparatide - administration & dosage</topic><topic>Teriparatide - adverse effects</topic><topic>Teriparatide - therapeutic use</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><topic>Thyroid Neoplasms - surgery</topic><topic>Thyroidectomy</topic><topic>Thyroidectomy - adverse effects</topic><topic>Vitamin D</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palermo, Andrea</creatorcontrib><creatorcontrib>Mangiameli, Giuseppe</creatorcontrib><creatorcontrib>Tabacco, Gaia</creatorcontrib><creatorcontrib>Longo, Filippo</creatorcontrib><creatorcontrib>Pedone, Claudio</creatorcontrib><creatorcontrib>Briganti, Silvia Irina</creatorcontrib><creatorcontrib>Maggi, Daria</creatorcontrib><creatorcontrib>Vescini, Fabio</creatorcontrib><creatorcontrib>Naciu, Anda</creatorcontrib><creatorcontrib>Lauria Pantano, Angelo</creatorcontrib><creatorcontrib>Napoli, Nicola</creatorcontrib><creatorcontrib>Angeletti, Silvia</creatorcontrib><creatorcontrib>Pozzilli, Paolo</creatorcontrib><creatorcontrib>Crucitti, Pierfilippo</creatorcontrib><creatorcontrib>Manfrini, Silvia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palermo, Andrea</au><au>Mangiameli, Giuseppe</au><au>Tabacco, Gaia</au><au>Longo, Filippo</au><au>Pedone, Claudio</au><au>Briganti, Silvia Irina</au><au>Maggi, Daria</au><au>Vescini, Fabio</au><au>Naciu, Anda</au><au>Lauria Pantano, Angelo</au><au>Napoli, Nicola</au><au>Angeletti, Silvia</au><au>Pozzilli, Paolo</au><au>Crucitti, Pierfilippo</au><au>Manfrini, Silvia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2016-11</date><risdate>2016</risdate><volume>101</volume><issue>11</issue><spage>4039</spage><epage>4045</epage><pages>4039-4045</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Context:
There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia.
Objective:
Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery.
Design:
This was a prospective phase II randomized open-label trial.
Setting:
This trial was set on a surgical ward.
Patients:
Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
Intervention:
Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
Main Outcome Measure:
Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured.
Results:
Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09–0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04)
Conclusions:
Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and vitamin D supplementation after discharge in high risk subjects after thyroid surgery.
Teriparatide may prevent post-thyroidectomy hypocalcemia, shorten the duration of hospitalization and reduce the need for calcium and vitamin D supplementation after discharge.</abstract><cop>United States</cop><pub>Endocrine Society</pub><pmid>27525532</pmid><doi>10.1210/jc.2016-2530</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4039-4045 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1835427859 |
| source | MEDLINE; Oxford Journals - Connect here FIRST to enable access; Free E-Journal (出版社公開部分のみ）; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Calcitriol Calcitriol - therapeutic use Calcium (blood) Calcium carbonate Calcium, Dietary - therapeutic use Dietary Supplements Drug Administration Schedule Female Goiter, Nodular - surgery Graves Disease - surgery Hormone Replacement Therapy - adverse effects Hospitalization Hospitals, University Humans Hypocalcemia Hypocalcemia - blood Hypocalcemia - epidemiology Hypocalcemia - etiology Hypocalcemia - prevention & control Incidence Injections, Subcutaneous Italy - epidemiology Length of Stay Male Middle Aged Parathyroid hormone Parathyroid Hormone - blood Patients Postoperative Complications - blood Postoperative Complications - epidemiology Postoperative Complications - etiology Postoperative Complications - prevention & control Prevention Risk Surgery Teriparatide - administration & dosage Teriparatide - adverse effects Teriparatide - therapeutic use Thyroid Thyroid gland Thyroid Neoplasms - surgery Thyroidectomy Thyroidectomy - adverse effects Vitamin D |
| title | PTH(1–34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A35%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTH(1%E2%80%9334)%20for%20the%20Primary%20Prevention%20of%20Postthyroidectomy%20Hypocalcemia:%20The%20THYPOS%20Trial&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Palermo,%20Andrea&rft.date=2016-11&rft.volume=101&rft.issue=11&rft.spage=4039&rft.epage=4045&rft.pages=4039-4045&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2016-2530&rft_dat=%3Cproquest_cross%3E1835427859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3164373648&rft_id=info:pmid/27525532&rft_oup_id=10.1210/jc.2016-2530&rfr_iscdi=true |